• SELECT SITE CURRENCY
Select a currency for use throughout the site
AmpliMed Corporation - Product Pipeline Review - H2 2011
Global Markets Direct, December 2011, Pages: 53
AmpliMed Corporation – Product Pipeline Review – H2 2011
Global Market Direct’s pharmaceuticals report, “AmpliMed Corporation - Product Pipeline Review - H2 2011” provides data on the AmpliMed Corporation’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, AmpliMed Corporation’s corporate website, SEC filings, investor presentations and featured press releases, both from AmpliMed Corporation and industry-specific third party sources, put together by Global Markets Direct’s team.
- AmpliMed Corporation - Brief AmpliMed Corporation overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of AmpliMed Corporation human therapeutic division.
- Overview of pipeline therapeutics across v
List of Tables
List of Figures
AmpliMed Corporation Snapshot
AmpliMed Corporation Overview
AmpliMed Corporation – Research and Development Overview
Key Therapeutic Areas
AmpliMed Corporation – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
AmpliMed Corporation – Pipeline Products Glance
AmpliMed Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
AmpliMed Corporation – Drug Profiles
Amplimexon + DTIC
Amplimexon + Gemcitabine
Amplimexon + Taxotere
AmpliMed Corporation – Pipeline Analysis
AmpliMed Corporation – Pipeline Products by Therapeutic Class
AmpliMed Corporation - Pipeline Products By Target
AmpliMed Corporation – Pipeline Products by Route of Administration